← Back to Clinical Trials
Recruiting NCT05025254

NCT05025254 Cognitive Testing Online in Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05025254
Status Recruiting
Phase
Sponsor McGill University
Condition Parkinson Disease
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2021-08
Primary Completion 2022-09

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
Neurocognitive testing

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2021-08 with a primary completion date of 2022-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a feasibility and pilot study. Though large-scale online neurocognitive testing is increasingly being done in psychiatry, there are no such efforts in Parkinson's research. Thus a large part of this pilot study will be to demonstrate feasibility and reliability, and use this experience to develop a feasible protocol for ongoing research. The specific short-term objectives are: 1. To establish the feasibility of performing large-scale deep cognitive phenotyping using online cognitive testing. 2. To demonstrate that online neurocognitive testing is valid and reliable in a smaller sample of locally recruited participants tested both in-lab and online.

Eligibility Criteria

Inclusion Criteria: * diagnosis of Parkinson's disease by neurologist or healthy individual with no diagnosis of any neurological illness Exclusion Criteria: * Psychotic spectrum disorders, active uncontrolled depression, advanced dementia (i.e. needing assistance with daily activities such as dressing or bathing), major stroke, major head injury, epilepsy requiring anti-seizure medications

Contact & Investigator

Central Contact

Madeleine Sharp, MD

✉ madeleine.sharp@mcgill.ca

📞 514-398-5174

Principal Investigator

Madeleine Sharp, MD

PRINCIPAL INVESTIGATOR

McGill University

Frequently Asked Questions

Who can join the NCT05025254 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, up to 90 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05025254 currently recruiting?

Yes, NCT05025254 is actively recruiting participants. Contact the research team at madeleine.sharp@mcgill.ca for enrollment information.

Where is the NCT05025254 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT05025254 clinical trial?

NCT05025254 is sponsored by McGill University. The principal investigator is Madeleine Sharp, MD at McGill University. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology